The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

作者： M. Jebbink , E. van Werkhoven , I. A. M. Mandjes , J. Wesseling , E. H. Lips

关键词:

摘要: The Neoadjuvant response index (NRI) has been proposed as a simple measure of downstaging by neoadjuvant treatment in breast cancer. It was previously found to predict recurrence-free survival (RFS) triple-negative (TN) at least accurate the standard binary system, absence or presence pathological complete remission (pCR), which is commonly employed outcome measure. NRI evaluated an independent consecutive series patients validate previous findings. Univariable and multivariable analyses were done assess predictive value clinical parameters for RFS. We combined original validation build model RFS after chemotherapy TN set (N = 108) confirmed that with higher-than-median (>0.7) had excellent (P 0.002), similar who achieved pCR. Multivariable analysis 191 showed strong predictor 0.0002), N-stage 0.001) T-stage 0.014) ranking second third, respectively. Importantly, among did not achieve pCR (NRI values below 1), higher still associated better method practical tool cancer treated chemotherapy. adds prognostic information could be useful compare efficacies different regimens.

参考文章(16)

L S Rigter, C E Loo, S C Linn, G S Sonke, E van Werkhoven, E H Lips, H A Warnars, P K Doll, A Bruining, I A Mandjes, M J Vrancken Peeters, J Wesseling, K G Gilhuijs, S Rodenhuis, Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer British Journal of Cancer. ,vol. 109, pp. 2965- 2972 ,(2013) , 10.1038/BJC.2013.661

Claudette E. Loo, H. Jelle Teertstra, Sjoerd Rodenhuis, Marc J. van de Vijver, Juliane Hannemann, Saar H. Muller, Marie-Jeanne Vrancken Peeters, Kenneth G. A. Gilhuijs, Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results American Journal of Roentgenology. ,vol. 191, pp. 1331- 1338 ,(2008) , 10.2214/AJR.07.3567

Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M Swain, Tatiana Prowell, Sibylle Loibl, D Lawrence Wickerham, Jan Bogaerts, Jose Baselga, Charles Perou, Gideon Blumenthal, Jens Blohmer, Eleftherios P Mamounas, Jonas Bergh, Vladimir Semiglazov, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, Wolfgang Eiermann, Gunter Von Minckwitz, None, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis The Lancet. ,vol. 384, pp. 164- 172 ,(2014) , 10.1016/S0140-6736(13)62422-8

Tarek M. Abdel-Fatah, Graham Ball, Andrew H.S. Lee, Sarah Pinder, R. Douglas MacMilan, Eleanor Cornford, Paul M. Moseley, Rafael Silverman, James Price, Bruce Latham, David Palmer, Arlene Chan, Ian O. Ellis, Stephen Y.T. Chan, Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer Clinical Cancer Research. ,vol. 21, pp. 1052- 1062 ,(2015) , 10.1158/1078-0432.CCR-14-0685

W. Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green, Aman U. Buzdar, S. Eva Singletary, Gabriel N. Hortobagyi, Lajos Pusztai, Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy Journal of Clinical Oncology. ,vol. 25, pp. 4414- 4422 ,(2007) , 10.1200/JCO.2007.10.6823

Irina Sachelarie, Michael L. Grossbard, Manjeet Chadha, Sheldon Feldman, Munir Ghesani, Ronald H. Blum, Primary Systemic Therapy of Breast Cancer Oncologist. ,vol. 11, pp. 574- 589 ,(2006) , 10.1634/THEONCOLOGIST.11-6-574

Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, Wolfgang Eiermann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiss, Michael Untch, Dirk Michael Zahm, Keyur Mehta, Sibylle Loibl, Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Journal of Clinical Oncology. ,vol. 31, pp. 3623- 3630 ,(2013) , 10.1200/JCO.2012.45.0940

Marco Colleoni, Vincenzo Bagnardi, Nicole Rotmensz, Giuseppe Viale, Mauro Mastropasqua, Paolo Veronesi, Anna Cardillo, Rosalba Torrisi, Alberto Luini, Aron Goldhirsch, A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. European Journal of Cancer. ,vol. 46, pp. 2216- 2224 ,(2010) , 10.1016/J.EJCA.2010.04.008

Julie R. Gralow, Harold J. Burstein, William Wood, Gabriel N. Hortobagyi, Luca Gianni, Gunter von Minckwitz, Aman U. Buzdar, Ian E. Smith, William F. Symmans, Baljit Singh, Eric P. Winer, Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease Journal of Clinical Oncology. ,vol. 26, pp. 814- 819 ,(2008) , 10.1200/JCO.2007.15.3510

10.

G. von Minckwitz, S. Loibl, M. Untch, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, J. Huober, C. Solbach, D. Lampe, V. Heyl, G. Hoffmann, F. Lorenz-Salehi, J. Hackmann, R. Schlag, C. Jackisch, G. Kunz, J.U. Blohmer, M. Hauschild, T. Fehm, V. Nekljudova, B. Gerber, K. Gnauert, B. Heinrich, T. Prätz, U. Groh, H. Tanzer, C. Villena, A. Tulusan, B. Liedtke, J.-U. Blohmer, K. Kittel, C. Mau, J. Potenberg, J. Schilling, M. Just, E. Weiss, U. Bückner, M. Wolfgarten, R. Lorenz, G. Doering, S. Feidicker, P. Krabisch, U. Deichert, D. Augustin, G. Kunz, K. Kast, G. von Minckwitz, C. Nestle-Krämling, M. Rezai, C. Höß, J. Terhaag, P. Fasching, P. Staib, B. Aktas, T. Kühn, F. Khandan, V. Möbus, C. Solbach, H. Tesch, E. Stickeler, G. Heinrich, H. Wagner, A. Abdallah, T. Dewitz, G. Emons, A. Belau, V. Rethwisch, T. Lantzsch, C. Thomssen, U. Mattner, A. Nugent, V. Müller, T. Noesselt, F. Holms, T. Müller, J.-U. Deuker, I. Schrader, D. Strumberg, C. Uleer, E. Solomayer, I. Runnebaum, H. Link, O. Tomé, H.-U. Ulmer, B. Conrad, G. Feisel-Schwickardi, H. Eidtmann, C. Schumacher, T. Steinmetz, I. Bauerfeind, S. Kremers, D. Langanke, U. Kullmer, A. Ober, D. Fischer, A. Kohls, W. Weikel, J. Bischoff, K. Freese, M. Schmidt, W. Wiest, M. Sütterlin, M. Dietrich, M. Grießhammer, D.-M. Burgmann, C. Hanusch, B. Rack, C. Salat, D. Sattler, J. Tio, E. von Abel, B. Christensen, U. Burkamp, C.-H. Köhne, W. Meinerz, S.-T. Graßhoff, T. Decker, F. Overkamp, I. Thalmann, A. Sallmann, T. Beck, T. Reimer, G. Bartzke, M. Deryal, M. Weigel, J. Huober, P. Weder, C.-C. Steffens, S. Lemster, A. Stefek, F. Ruhland, M. Hofmann, J. Schuster, W. Simon, U. Kronawitter, M. Clemens, T. Fehm, W. Janni, K. Latos, W. Bauer, A. Roßmann, L. Bauer, Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) Annals of Oncology. ,vol. 25, pp. 2363- 2372 ,(2014) , 10.1093/ANNONC/MDU455

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

来源期刊

我的账户

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

来源期刊

相似文章 3

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.

Handling Neoadjuvant Therapy Specimens

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.

我的账户